MedTrace Logo

Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD

NCT02218177 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2018-10-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the level of cytokines (which are small proteins important in cell signalling) in eye fluid (aqueous humour) in patients with wet age related macular degeneration patients who have been treated with an injection in the eye (intravitreal injection) with a drug called ranibizumab. The level of cytokines will be compared between patients who have a good response to ranibizumab treatment and patients who are non-responsive to ranibizumab and need other forms of therapy. This knowledge will help for the future treatment and to potentially develop new medication for wet age-related macular degeneration.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

Aflibercept

anti-VEGF treatment for wet age related macular degeneration

DRUG

Ranibizumab

anti-VEGF treatment for wet age related macular degeneration

PROCEDURE

Combination Photodynamic Therapy

Use of cold laser with an intravitreal injection of dexamethasone to treat wet age related macular degeneration

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Wai-Ching Lam, MD · Toronto Western Hospital, University Health Network, University of Toronto

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-08-31
Completion
2016-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02218177 on ClinicalTrials.gov